Compare IHS & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHS | ITGR |
|---|---|---|
| Founded | 2001 | 1970 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2021 | 2000 |
| Metric | IHS | ITGR |
|---|---|---|
| Price | $7.62 | $84.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $9.32 | ★ $95.00 |
| AVG Volume (30 Days) | ★ 1.1M | 628.4K |
| Earning Date | 11-12-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.37 | ★ 2.42 |
| Revenue | $1,765,825,000.00 | ★ $1,831,074,000.00 |
| Revenue This Year | $3.49 | $9.58 |
| Revenue Next Year | $2.77 | N/A |
| P/E Ratio | ★ $5.88 | $34.12 |
| Revenue Growth | N/A | ★ 9.54 |
| 52 Week Low | $3.02 | $62.00 |
| 52 Week High | $8.21 | $146.36 |
| Indicator | IHS | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 69.60 |
| Support Level | $7.34 | $81.89 |
| Resistance Level | $8.21 | $85.23 |
| Average True Range (ATR) | 0.27 | 2.00 |
| MACD | 0.02 | 0.50 |
| Stochastic Oscillator | 45.54 | 92.57 |
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.